The comprehensive screening and evaluation of carnitine changes in patients with depression is of great significance to studying the development of depression in depth
Many patients report improvements in self-esteem, body image, and overall quality of life
According to clinical trials and the Wegovy SmPC, semaglutide commonly causes nausea (occurring in up to 44% of patients), vomiting (approximately 25%), diarrhoea (30%), constipation, and abdominal discomfort, particularly during dose escalation
Our approach combines prescription medications with nutritional counseling, metabolic optimization, and ongoing support to ensure long-lasting results
Avoid high-fat foods during the first 48 hours after injection